Want to track ANNX and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Annexon: Complement Inhibition Of GBS Only The Beginning With Strong Tech In Place
Annexon, Inc. primary endpoint met with statistical significance in phase 3 Bangladesh and Philippines study, using ANX005 for the treatment of patients with Guillain-Barré syndrome. Results from RWS IGOS phase 3 study, using ANX005 for the treatment of patients with GBS, expected 1st half of 2025. If the primary endpoint of the RWS IGOS protocol study achieves a positive outcome, then a BLA filing is expected in the 1st half 2025.
Seekingalpha | 2 years ago
Annexon's neurological disorder drug meets main goal of late-stage study
Annexon Inc said on Tuesday its experimental drug to treat a rare neurological disorder met the main goal of a late-stage trial.
Reuters | 2 years ago
2026 © Marketlog. All Rights Reserved.
